NTRK1, 2 and 3 Fusion with Interpretation
| Label Mnemonic: | NTRKBM |
| Epic code: | LAB8825 |
| Downtime form: | Doctor/Provider Orders - Pathology Molecular |
Molecular Pathology
6240 RCP
384-9568
6240 RCP
384-9568
Specimen(s):
Bone Marrow
Collection Medium:
 |
| Pink top tube 6 mL (K2-EDTA) |
Minimum:
2 mL Bone Marrow in EDTA pink top tube
Rejection Criteria:
Specimens that have been decalcified will not be accepted.
Turn Around
Time:
10-14 days upon receipt in laboratory
Reference Range:
Fusion or mutation not detected
Comments:
The panel targets gene rearrangements of the NTRK1,
NTRK2 and NTRK3. NTRK gene rearrangements represent
the fusion between NTRK1, NTRK2, or NTRK3
with various partner genes that result in constitutive kinase
activity.
NTRK gene rearrangements are found at high frequencies in rare cancer types including secretory carcinoma of the breast and salivary gland, congenital or infantile fibrosarcoma and at lower frequencies (commonly <1%) in a range of other tumor types.
The FDA granted approval for use of larotrectinib for adult and pediatric patients with solid tumors that have NTRK gene rearrangements that are either metastatic or non-resectable, who have no satisfactory alternative treatments or whose cancer has progressed following treatment (based on data from the LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431) clinical trials).
NTRK gene rearrangements are found at high frequencies in rare cancer types including secretory carcinoma of the breast and salivary gland, congenital or infantile fibrosarcoma and at lower frequencies (commonly <1%) in a range of other tumor types.
The FDA granted approval for use of larotrectinib for adult and pediatric patients with solid tumors that have NTRK gene rearrangements that are either metastatic or non-resectable, who have no satisfactory alternative treatments or whose cancer has progressed following treatment (based on data from the LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431) clinical trials).
Methodology:
Total nucleic acid including RNA is isolated from tumor specimens.
Reverse transcription, anchored multiplexed PCR for targeted next-
generation sequencing is performed.
CPT Code:
81194